8-K 1 dp148243_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

March 24, 2021 (March 18, 2021)

 

EUROPEAN BIOTECH ACQUISITION CORP.

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-40211   N/A

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

Johannes Vermeerplein 9

1071 DV Amsterdam, Netherlands

31 (0) 20 664 55 00

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

Not Applicable
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A ordinary shares, par value $0.0001 per share   EBAC   The Nasdaq Capital Market
Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   EBACW   The Nasdaq Capital Market
Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant   EBACU   The Nasdaq Capital Market
         

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Item 8.01. Other Events.

 

On March 18, 2021, European Biotech Acquisition Corp. (the “Company”) consummated its initial public offering (“IPO”) of 12,000,000 units (the “Units”). Each Unit consists of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Ordinary Shares”), and one-third of one redeemable warrant of the Company (“Warrant”), each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share. The Units were sold at a price of $10.00 per unit, generating gross proceeds to the Company of $120,000,000.

 

Substantially concurrently with the closing of the IPO, the Company completed the private sale (the “Private Placement”) of 440,000 Units (the “Private Placement Units”) to LSP Sponsor EBAC B.V. (the “Sponsor”) at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to the Company of $4,400,000. In addition, the Sponsor currently owns 3,400,000 Class B ordinary shares, which will automatically convert into Class A Ordinary Shares at the time of the Company's initial business combination or earlier at the option of the holders thereof as described in the Company's registration statement.

 

A total of $120,000,000, comprised of $117,600,000 of the proceeds from the IPO, including $4,200,000 of the underwriters’ deferred discount, and $2,400,000 of the proceeds of the sale of the Private Placement Units, was placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee. An audited balance sheet as of March 18, 2021 reflecting receipt of the proceeds upon consummation of the IPO and the Private Placement has been issued by the Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Audited Balance Sheet, as of March 18, 2021

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 24, 2021

 

  EUROPEAN BIOTECH ACQUISITION CORP.
   
   
  By: /s/ Eduardo Bravo Fernandez de Araoz
    Eduardo Bravo Fernandez de Araoz
    Chief Executive Officer